Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

OXBRYTA Principal Display Panel (voxelotor)

PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label

NDC 72786-101-01
Rx only

Oxbryta®
(voxelotor) tablets

500 mg

Swallow tablets whole.
Do not cut, crush, or chew the tablets.

90 tablets

PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 300 mg Tablet Bottle Label

NDC 72786-111-03
Rx only

Oxbryta®
(voxelotor)

Tablets for Oral Suspension

300 mg

90 tablets

PRINCIPAL DISPLAY PANEL - 300 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 300 mg Tablet Bottle Label - 72786-102

NDC 72786-102-03
Rx only

Oxbryta®
(voxelotor) tablets

300 mg

Swallow tablets whole.
Do not cut, crush, or chew the tablets.

90 tablets

PRINCIPAL DISPLAY PANEL - 300 mg Tablet Bottle Label - 72786-102
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event